Clarification regarding the management’s role during the restructuring period
January 9, 2025
CombiGene AB (publ) (“CombiGene”, the “Company”) would like to clarify this morning’s memo by stating that
CombiGene AB (publ) (“CombiGene”, the “Company”) would like to clarify this morning’s memo by stating that
The Board of CombiGene AB (publ) (“CombiGene”, the “Company”) today announces that a first step has
CombiGene AB (publ) (“CombiGene”, the “Company”) announces today that Annika Ericsson, current Director Preclinical Development, will
CombiGene AB (“CombiGene”, the “Company”) today announces that CEO Jan Nilsson will leave his position as
STOCKHOLM — On September 27, 2022, CombiGene (“CombiGene”, the “Company”) announced that Peter Ekolind joins the
In 2021, CombiGene’s epilepsy project CG01 will focus on the final preclinical studies. In parallel, the
In 2021, CombiGene’s epilepsy project CG01 will focus on the final preclinical studies, not least the
During 2018 CombiGene is entering a decisive phase with focus on development of a manufacturing method